Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 5.05%
As of Thursday, September 10, Tectonic Therapeutic, Inc.’s TECX share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 9.03%
As of Monday, August 31, Tectonic Therapeutic, Inc.’s TECX share price has dipped by 9.03%, which has investors questioning if this is right time to buy.Michael Rose
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 12.56%
As of Monday, August 31, Tectonic Therapeutic, Inc.’s TECX share price has dipped by 12.56%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Up 5.55%
As of Tuesday, August 18, Tectonic Therapeutic, Inc.’s TECX share price has surged by 5.55%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Up 5.43%
As of Wednesday, August 12, Tectonic Therapeutic, Inc.’s TECX share price has surged by 5.43%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | TECX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $567.9 | $269.3 | 38% |
|
| Shares Out (Mil) | 19.0 | 54.0 | 30% |
|
| Institutional Ownership | 67.6% | 93.0% | 42% |
|
| Float (Mil) | 11.9 | 42.2 | 21% |
|
| Beta | 0.22 | 0.95 | 13% |
|
| Avg Daily Volume (000s) | 224 | 473 | 47% |
|
| Price Change (52-week) |
67.8% | 55.9% | 87% |
|
| Growth | TECX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TECX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($86) | ($43) | 12% |
|
| EPS (TTM) | ($4.564) | ($1.500) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($72) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($60) | $2 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 21% |
|
| Enterprise Value (Q1) (Mil) | $383 | $182 | 31% |
|
| Valuation | TECX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.50 | 2.62 | 59% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | TECX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (73.5%) | na |
|
| ROA | (32.2%) | (47.9%) | 16% |
|
| ROE | (33.8%) | (55.0%) | 19% |
|
| Liabilities to Assets | 5.6% | 29.5% | 3% |
|
| F-Score | 1 | 3 | 1% |
|
Tectonic Therapeutic, Inc. did not pass any screens on 9/11/2026.
